Presented at Regional ONS Chapters: Targeting the DNA Damage Response Pathway: The Evolving Role of PARP Inhibitors in Cancer Therapy
Presented at AMCP: NSCLC EGFR-Targeted Therapies: The Pharmacist’s Role in Tailoring Therapy and Improving Patient Outcomes
Presented at HOPA: NSCLC EGFR-Targeted Therapies: The Oncology Pharmacist’s Role in Tailoring Therapy and Improving Patient Outcomes
Presented at AACR: Targeting DNA Damage Response: At the Forefront of Emerging Concepts and Strategies
Presented at the 2017 ONS National Meeting: Targeting the DNA Damage Response Pathway: The Evolving Role of PARP Inhibitors in Cancer Therapy
Presented at AUA: Role of Immune Checkpoint Inhibitors in Locally Advanced or Metastatic Bladder Cancer: The Urologist’s Perspective
Presented at ASCO: EXPERT EXCHANGE: Advances in Biomarker-Driven Immune Checkpoint Blockade for Selected Types of Solid Tumors
Presented at ASCO: EXPERT EXCHANGE: Management of Advanced EGFR Mutation-Positive NSCLC: Making Bold Strides Toward True Precision Medicine
